{"id":"NCT05696080","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","officialTitle":"A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 Years of Age With Increased Risk for Pneumococcal Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-02-13","primaryCompletion":"2024-02-16","completion":"2024-02-16","firstPosted":"2023-01-25","resultsPosted":"2025-02-26","lastUpdate":"2025-02-26"},"enrollment":518,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infection"],"interventions":[{"type":"BIOLOGICAL","name":"V116","otherNames":["Pneumococcal 21-valent Conjugate Vaccine"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"PCV15","otherNames":["VAXNEUVANCE™"]},{"type":"BIOLOGICAL","name":"PPSV23","otherNames":["PNEUMOVAX™23"]}],"arms":[{"label":"V116 + Placebo","type":"EXPERIMENTAL"},{"label":"PCV15 + PPSV23","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from 23 of the serotypes causing disease in adults) post-vaccination within each vaccination group separately.","primaryOutcome":{"measure":"Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination","timeFrame":"Up to 5 days following each vaccination","effectByArm":[{"arm":"V116 + Placebo","deltaMin":9.1,"sd":null},{"arm":"PCV15 + PPSV23","deltaMin":25.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":20},"locations":{"siteCount":44,"countries":["United States","Australia","Canada","Chile","Japan","New Zealand","Poland","South Korea"]},"refs":{"pmids":[],"seeAlso":["https://www.merckclinicaltrials.com/","https://msd.trialsummaries.com/Study/StudyDetails?id=26329&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":386},"commonTop":["Injection site pain","Fatigue","Headache","Injection site swelling","Injection site erythema"]}}